ENTX - Company ID 0001638097
The table below shows Entera Bio Ltd.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.09M | -$1.40M | -$1.86M | -$1.61M | -$4.79M | -$2.32M |
| Capital expenditure | $0.00 | $8.00K | $0.00 | $11.00K | $23.00K | $0.00 |
| Investing cash flow | $0.00 | -$8.00K | $0.00 | -$11.00K | -$23.00K | $0.00 |
| Dividends paid | - | - | - | - |
Entera Bio Ltd. reported operating cash flow of -$7.37M for fiscal year 2025. That is down 8.1% from -$6.82M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow grew from -$10.56M (FY 2020) to -$7.37M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $130.00K | $13.34M | $30.00K | $0.00 | $0.00 | $10.11M |